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Summary 
The molecular and cellular mechanisms responsible for cytotoxic T lymphocyte (CTL)-induced 
immunopathology are not well defined. Using a model in which hepatitis B surface antigen 
(HBsAg)-specific  CTL cause an acute necroinflammatory  liver disease in HBsAg transgenic mice, 
we demonstrate that class I-restricted disease pathogenesis is an orderly, multistep process that 
involves direct as well as indirect consequences of CTL activation. It begins (step 1) almost 
immediately as a direct antigen-specific  CTL-target cell interaction that triggers the HBsAg- 
positive hepatocyte to undergo programmed cell death (apoptosis).  It progresses (step 2) within 
hours to a focal inflammatory response in which antigen-nonspecific  lymphocytes and neutrophils 
amplify the local cytopathic effect of the CTL. The most destructive pathogenetic function of 
the CTL, however, is to secrete interferon 3' when they encounter antigen in vivo, thereby activating 
the intrahepatic macrophage and inducing a delayed-type hypersensitivity response (step 3) that 
destroys the liver and kills the mouse. We propose that the principles illustrated in this study 
are generally applicable to other models of class I-restricted, CTL-induced immunopathology, 
and we suggest that they contribute to the immunopathogenesis  of viral hepatitis during hepatitis 
B virus infection in humans. 
V 
iral clearance and disease pathogenesis in noneytopathic 
viral infections are generally thought to represent linked 
consequences of an MHC class I-restricted CTL response to 
viral antigens expressed by infected cells. Since class I-restricted 
CTL are defined by their ability to specifically recognize and 
destroy target cells in vitro, it is generally assumed that this 
is also their principal function in vivo. This has never been 
proven, however. In fact, with respect to viral clearance, re- 
cent studies have demonstrated that HIV-spedfic CTL can 
control HIV replication by a noncytolytic mechanism (1, 
2),  and HSV replication can be prevented by HSV-specific 
CTL at noncytolytic E/T cell ratios in vitro (3).  Further- 
more, influenza virus-specific CTL can lead to strain-specific 
viral clearance in vivo, without any attendant pathological 
consequences (4),  and lymphocytic choriomeningitis virus 
(LCMV)  1 can be cleared from the spleen, by the adoptive 
transfer of as few as 200 LCMV-specific CTL (5). Thus, it 
1 Abbreviations  used in thispaper: BrdU, bromodec~yuridine; DTH, delayed 
type hypersensitivity; ER, endoplasmic reticulum; HBV, hepatitis B virus; 
HBsAg, hepatitis B surface antigen; I.CMV, lymphocyte choriomeningitis 
virus; LDH, lactic dehydrogenase; sALT, serum alanine aminotransferase. 
would appear that the virus control function of class I-re- 
stricted CTL can be expressed independently of their cyto- 
toxic potential in vitro and in vivo. 
With respect to tissue injury, although dass I-restricted, 
antigen-specific CTL can cause allograft rejection (6, 7), tumor 
regression (8, 9), or necroinflammatory diseases in infected 
mice (10, 11), direct lysis of target cells by the CTL has not 
been demonstrated in these models. Instead, it has been sug- 
gested that CTL-induced indirect secondary events might play 
a dominant role in class I-restricted tissue injury (12, D), 
like the delayed-type hypersensitivity (DTH) reaction plays 
in class II-restricted autoimmune disease models, such as ex- 
perimental autoimmune encephalitis (14-16), thyroiditis (17), 
orchitis (18), and insulin-dependent diabetes in the nonobese 
diabetic mouse (19). 
We have previously demonstrated that dass I-restricted hep- 
atitis B surface antigen (HBsAg)-spedfic spleen cells and doned 
CTL cause a necroinflammatory disease when they are in- 
jected into HBsAg transgenic mice (20).  Recently, we have 
demonstrated that such CTL directly bind and induce the 
cytological changes characteristic  of programmed cell death 
(apoptosis)  in HBsAg-positive hepatocytes shortly after in- 
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Volume 178  November  1993  1541-1554 jection into such animals (Ando, K., T. Moriyama, S. Wirth, 
L. G. Guidotti, R. D. Schreiber, H. J. Schlist, S.-n. Huang, 
and F. V. Chisari, manuscript submitted for publication). In 
the current study we show that that disease severity is not 
primarily determined by the direct cytotoxic potential of the 
CTL in this model.  Instead, it depends on CTL-activated 
downstream  events involving the  recruitment  of antigen- 
nonspecific inflammatory cells, as well as amplification mech- 
anisms that the CTL activate by releasing IFN-y when they 
recognize antigen in vivo, and that the intrinsic sensitivity 
of the target hepatocyte to destruction by these mechanisms 
contributes significantly to the severity of the resultant dis- 
ease.  Furthermore, it is apparent that class  I-restricted dis- 
ease pathogenesis, in this model, is an orderly, multistep process 
that progresses from direct CTL-induced single cell necrosis 
to a focal inflammatory response that locally amplifies the 
cytopathic effect of the CTL, and that it culminates in a gener- 
alized DTH reaction that can destroy the liver and kill the 
mouse. 
Materials and Methods 
HBsAg-specific  CTL.  Two  independently  derived  CD3 +, 
CD4-,  CD8 + CTL clones (designated  6C2 and D10) that have 
been described in detail elsewhere (20, Ando, K. et al., manuscript 
submitted for publication)  were used in this study.  Both clones 
are Ld restricted,  recognize  an epitope (IPQSLDSWWTSL) that 
is located between residues 28-39 of HBsAg, and secrete IFN-y 
but not (TNF-o~) after antigen stimulation in vitro (Ando, K. et 
al., manuscript submitted for publication).  They were maintained 
by weekly restimulation with irradiated P815 cells that stably ex- 
press the hepatitis B virus (HBV) large envelope protein (ayw sub- 
type) containing HBsAg, as previously described (20, and Ando, 
K. et al.,  manuscript submitted for publication). 
HBV Transgenic Mice.  Production and characterization  of the 
transgenic  mouse lineages used in these studies have been previ- 
ously described (21-25). These lineages were selected because they 
do not develop any evidence of spontaneous liver disease and be- 
cause  they display  lineage-specific  differences  in  hepatocellular 
HBsAg expression that permit investigation of several quantitative 
and qualitative aspects of class I-restricted CTL-target cell interac- 
tion in vivo. 
Most studies were performed in lineage 107-5D (official desig- 
nation Tg[Alb-1,HBV]Bri66),  (inbred  B10.D2,  H-2  a) in which, 
constitutively, the HBV envelope coding region is under the con- 
trol of the mouse albumin promoter. The HBV large envelope poly- 
peptide forms long nonsecretable filamentous HBsAg particles that 
are retained within the endoplasmic reticulum (EK) of the hepato- 
cyte where they are readily detectable immunohistochemically  (21, 
and see Fig. 4 D, this paper). Selected experiments  were also per- 
formed with mice in which this transgene had been backcrossed 
onto a B10.S (H-2')  background (lineage  107-5S). 
Lineage 23-3 (official designation Tg[MT-1,HBV]Bri28), (inbred 
C57BI/6, H-2b), expresses the HBV large envelope polypeptide 
under the control of the zinc inducible mouse metaUothionein pro- 
moter. In the absence of dietary zinc supplementation, an internal 
HBV promoter, which is present within the envelope coding re- 
gion in the transgene,  drives expression of the HBV major enve- 
lope polypeptide which is effectively secreted by the hepatocyte into 
the circulation such that hepatocellular HBsAg is barely detectable 
immunohistochemicaUy (21, and see Fig. 3 A, this paper). Activa- 
tion of the metallothionein promoter by oral zinc administration 
leads to production of the HBV large envelope polypeptide by the 
hepatocyte, resulting in retention of HBsAg in the ER (as in lin- 
eage 107-5 above), where it is detectable principally in periportal 
hepatocytes close to the point of entry of the circulation into the 
hepatic lobule (21, and see Fig. 3 C, this paper). 
Lineage pFC80-219 (official designation Tg[HBs,  HVB]Chi219), 
(inbred  C57B1/6,  H-2  b) expresses only the HBV major envelope 
polypeptide under the transcriptional control of HBV regulatory 
elements.  These mice secrete large quantities of HBsAg into the 
circulation  and do not retain any immunohistochemically detect- 
able HBsAg in their hepatocytes  (23, 24,  and see Fig. 4 F, this 
paper). For these studies, lineages 23-3 and pFC80-219 were back- 
crossed  one  generation  against  B10.D2  to  produce  H-2  bxd  F1 
hybrids before injection of the H-2a-restricted  CTL (23-3  ~  and 
pFC80-219b~). 
The intrahepatic distribution of HBV antigens was assessed by 
the indirect immunoperoxidase  method using 3-amino-9-ethyl car- 
bazole (Shandon-Lipshaw, Pittsburgh, PA) as a coloring substrate, 
as previously described (25). Duplicate sections were also stained 
with normal rabbit serum as the primary antibody to serve as nega- 
tive controls.  HBsAg positive human and transgenic  mouse liver 
tissue served as assay controls. 
Disease Model.  5 d after the last stimulation, CTL were washed, 
counted, suspended in HBSS containing 2% FCS, and injected in- 
travenously or intraperitoneally into transgenic and nontransgenic 
recipients. HepatoceUular injury was monitored biochemically by 
measuring serum alanine aminotransferase  (sALT) activity (25). 
Results were expressed as mean sALT activity _+ SEM and differ- 
ences between experimental and control groups were assessed for 
statistical significance by Student's t test. Mice were killed by cer- 
vical dislocation, and necropsy was performed. Tissue samples were 
fixed in 10% zinc buffered formalin (Anatek, Ltd, Battle Creek, 
MI), embedded in paraffin, sectioned (3 #) and stained with hema- 
toxylin and eosin as described (25). The number of hepatocytes 
and intrahepatic inflammatory  cells were counted in at least 50 high 
power (x 400) fields and the results were expressed as the number 
of cells per mm  2 of liver tissue. Standard cytopathological criteria 
were used to define the various components of the inflammatory 
response. Lymphocytes and macrophages were identified immuno- 
histochemically in snap-frozen, acetone-fixed tissue using rat mAbs 
to L3T4, Lyt-2, and Mac-1 according to the manufacturer's instruc- 
tions (Boehringer Mannheim Corp., Indianapolis,  IN). 
Quantitation oflntrahelmtic CTL.  In selected experiments, CTL 
clones were incubated with 50 mM bromodeoxyuridine (BrdU; 
Sigma Chemical Co., St. Louis, MO) for 2 d in vitro before injec- 
tion into HBV transgenic mice. Immunocytochemical analysis be- 
fore injection (see below) revealed that >98%  of the CTL were 
labeled by this procedure, and functional analysis revealed that the 
cytolytic activity of the CTL was unaffected by the BrdU labeling 
process. To detect BrdU-positive CTL in tissue, paraffin-embedded 
tissue sections were treated with 3% H202 at room temperature 
and with 0.05% pepsin in 0.01N HCI (37~  20 min). Slides were 
rinsed  and incubated in 1 N  HCI (60 min, room temperature), 
washed with PBS (pH 7.4), blocked with normal goat serum for 
30 rain at room temperature, and incubated overnight at 4oC in 
a humid chamber with a 1/100 dilution of mouse monoclonal anti- 
BrdU antibody (Becton Dickinson & Co., Mountain View, CA). 
After washing with PBS, the tissue sections were incubated with 
biotinylated goat F(ab' h  anti-mouse IgG (Sigma Chemical Co.) 
at a 1/50 dilution (30 min, 37~  The slides were then washed 
with PBS and incubated with Streptavidin-horseradish  peroxidase 
conjugate (Extravidin;  Sigma Chemical Co.) at a 1/600 dilution 
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Diaminobenzidine  (DAB)-Cobalt-H202  (5 min,  room tempera- 
ture),  and the slides were counterstained  with hematoxylin  and 
eosin before mounting. 
Functional Role of  Host-derived  Inflammatory Cells.  Groups of mice 
received 900 rad of gamma irradiation  (Gamma Cell 40; Atomic 
Energy of Canada, Ont., Canada) 6 d before the transfer of CTL, 
thereby reducing  the number of spleen cells more than  100-fold 
before CTL injection (data not shown). Other mice were injected 
intraperitoneally  with 1 ml of carrageenan (type 2; Sigma Chem- 
ical Co.) dissolved and sterilized by boiling in sterile nonpyrogenic 
PBS, at a concentration  of 2 mg/ml as previously described (26, 
27) on days -4,  -3,  -2,  -1, and 0 relative to CTL administra- 
tion. Control mice received 1 ml of PBS at the same times before 
CTL administration.  Sdected animals were injected intravenously 
with India ink (0.2 ml; CII/1431a, diluted threefold; Pelikan Spezi- 
altusche,  Hannover,  Germany) 24 h before killing (28) to assess 
the influence of irradiation or carrageenan injection on tissue mac- 
rophages. 
Role oflFN- y and TNF-cr.  To evaluate the role of IFN-3' and 
TNF-~ in the disease process, CTL were administered 24 h before 
or after the intraperitoneal  injection of hamster mAbs H22 and 
TN3 19.12 specific for murine IFN-'y and TNF-c~, respectively (29, 
30). Purified hamster IgG (Jackson ImmunoResearch, West Grove, 
PA) was used as a control antibody. All antibodies were diluted 
to a concentration  of 250 rag/200  ml with nonpyrogenic  PBS 
(GIBCO BRL, Gaithersburg,  MD) just before administration. 
Mouse Hepatocyte Culture.  To assess the direct hepatocytotoxic 
potential of IFN-'y and TNF-ot, primary transgenic and nontrans- 
genie hepatocytes were incubated with various concentrations  of 
recombinant  murine IFN-3~ (sp act 5.2  x  106 U/rag) and recom- 
binant  murine  TNF-ot  (sp act  1.2  x  106 U/mg),  which  were 
generously provided by Dr. Susan Kramer (Genentech, Inc., South 
San Francisco, CA). For these studies, hepatocyte suspensions were 
prepared by perfusion of transgenic and nontransgenic mouse livers 
with  20 ml of Ca  2+  free PBS containing  EGTA (190 mg/liter; 
Sigma Chemical Co.) and 30 ml of HBSS containing collagenase 
(500 mg/liter, 0.9 U/mg; Serva, Westbury, NY) and CaC12 (420 
mg/liter; Sigma Chemical Co.) at 37~  The ceils were suspended 
in EHAA medium (GIBCO BILL) containing  10% FCS at 4~ 
filtered through No. 150 mesh, and centrifuged  three times (50 
g,  1 min).  Purified hepatocytes were resuspended (5  x  10S/ml) 
in the same medium and plated (2 ml/well) in 6-well plates (Coming 
Inc., Coming, NY). 4 h later, the supernatant was removed from 
the adherent  cells and replaced with 2 ml fresh EHAA medium 
containing  10% FCS, epidermal growth factor (20 ng/ml) and in- 
sulin (10 -9 M; all from Sigma Chemical Co.). After overnight in- 
cubation,  the cells were fed with 1 ml of fresh media. 24 h later, 
the supernatants  and cell lysates (1% Triton X, 1 ml/well) were 
analyzed for ALT or lactic dehydrogenase (LDH) activity as previ- 
ously described (25). Cytokine-mediated  cytotoxic activity was ex- 
pressed as percent ALT or LDH release calculated as follows 100 
x  (ALT or LDH in medium/ALT or LDH in Triton X). 
Results 
HBsAg-specific  CTL Induce an Acutely Fatal Necroinflamma- 
tory Liver Disease (Fulminant Hepatitis)  in HBsAg  Transgenic 
Mice.  Two independently  derived  CD3 §  CD4-,  CD8 + 
CTL clones, designated 6C2 and D10 were used in this study 
because of their excellent cytotoxic and growth characteris- 
tics in vitro.  Both clones,  studied sequentially over a 2-yr 
period, displayed virtually identical behavior in vitro and in 
vivo. Most studies were performed by injection of clone 6C2 
into lineage  107-5D,  with confirmatory studies performed 
in other lineages and with clone D10.  Upon injection into 
HBsAg-positive transgenic mice lineage (107-5D), both clones 
D10  and  6C2  were  shown  to  induce  an  acute,  H-2  a re- 
stricted, lethal necroinflammatory  liver disease that reaches 
peak severity within 24-72 h and resolves completely (in sur- 
vivors) 7-10 d later. 
Sex Dependence.  As shown for clone 6C2 (Fig.  1 A), the 
severity of liver disease (measured biochemically as sALT ac- 
tivity) was approximately four times greater in males (13,650 
+_  2,130 U/liter)  than  in females (3,740  _+  1,267 U/liter) 
(p <0.005) after i.v. administration  of 107 CTL (Fig.  2 A). 
The same is true for the disease severity observed after CTL 
administration  to  lineages  23-3  and  pFC80-219  (data  not 
shown). The reason for this difference has not been defined, 
but it might  be due to higher  intracellular  concentrations 
of HBsAg in males than in females.  Indeed, we have shown 
(25) that intrahepatic HBsAg content is greater in males than 
in females in an independent lineage (50-4) that contains the 
same transgene as lineage 107-5.  Because of this difference, 
all  subsequent studies were performed in males. 
Route of  Administration.  Disease severity was also influenced 
by the route of CTL administration  (Fig.  1 B). sALT levels 
rose more than 100-fold after the intravenous injection of 107 
CTL into lineage  107-5D males,  as compared with only a 
10-fold increase after intraperitoneal injection. Using BrdU- 
labeled CTL, the number of CTL that localized to the liver 
after intraperitoneal injection was found to be less than that 
observed after intravenous  injection  (data not  shown). 
CTL Dose and MHC Dependenc~  Disease severity was also 
strictly CTL dose dependent in lineage 107-5D recipients in 
which the transgene was expressed in the context of an H-2  d 
genetic background (Fig. 2 A). Liver disease was detectable 
biochemicaUy as progressively increasing sALT activity at CTL 
doses above l0 s CTL per mouse.  At  107 CTL  per mouse, 
the resultant liver disease was severe enough to be fatal within 
96 h in 7/15 recipients (46.7%),  and it was fatal for all  10 
mice (100%) that received 1.5  x  107 CTL (Fig.  2 B). In the 
same study,  10 r CTL failed to induce liver disease in trans- 
genic recipients that expressed the same transgene in the con- 
text of an H-2 * genetic background (Fig. 2 A), in keeping 
with  the demonstration  that  the CTL  are  L a restricted  in 
vitro (Ando, K. et al., manuscript submitted for publication). 
Importantly, as shown in Fig. 2, treatment of the mice with 
antibodies to IFN-  3, before CTL administration  completely 
protected the mice against fatal liver disease (see below for 
additional  details). 
Intrahepatic HBsAg  Content.  Using lineage 23-3 H-2  bxd 
F1 males  derived from  transgenic  (H-2  b) parents  that  had 
been bred  with  nontransgenic  B10.D2  (H-2  a)  mates,  we 
demonstrated that  the severity of liver disease was directly 
related to the total intrahepatic  HBsAg content in  the re- 
cipients. Under baseline conditions in this lineage, the hepa- 
tocytes secrete HBSAg so rapidly that it is not detectable in 
the liver (Fig.  3 A) even though it can reach 10-fold higher 
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Figure  1.  CTI,induced liver disease  in HBsAg-positive t~sgenic mice 
depends on the route of admi-;stration and the s= of the r~pient. (A) 
CTL-induced  liver disease in lineage 107-5D recipients is more severe in 
males than in females. Serum ALT activity was analyzed at varying times 
relative to the injection of 107 CTL (clone 6C2) into groups of three age- 
matched male and female littermates. (B) 107 CTL (clone 6C2) were in- 
jected either intravenously or intraperitoneally  into lineage 107-5D trans- 
genic male recipients. 
concentrations in the blood than lineage 107-5 (21). In con- 
trast, when synthesis of the HBV large envelope polypeptide 
is induced by activating the metallothionein promoter with 
oral zinc sulfate, nonsecretable filamentous HBsAg particles 
are formed and retained within the EK where they can be 
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CTL-induced  liver disease  and  mortality depends on  the 
number of CTL administered and the MHC class I haplotype of the recip- 
ient. (A) sALT activity was monitored daily after the injection of varying 
doses of clone 6C2 CTL into lineage 107-5D  (H-2  d) and 107-5S (H-2,) 
transgenic mice. (B) Results reflect mortality after intravenous  injection 
of 10  s, 106, 107, or 1.5  x  107 CTL into groups of 6, 6,  15, and 10 lin- 
eage 107-5D male recipients, respectively. Six animals were injected with 
107 CTL 24 h after the intraperitoneal administration of 500/~g of ham- 
ster anti-IFN-'y mAb. 
Figure  3.  The severity of CTL-induced fiver disease is a function of HBsAg retention by the bepatocyte. Lineage 23-2  ~'~ transgenic  males cont2ining 
the zinc inducible mouse metallothionein promoter were injected with 107 CTL (done 6C2).  Selected animals were pretreated with zinc sulfate as 
a 0.75%  solution in the drinking water for 14 d before CTL administration. (.4 and C) The intrahepatic content of FIBsAg before  and after zinc 
administration (immunocytochemical staining for HBsAg,  x200). Note the presence of very rare, faintly HBsAg-positive hepatocytes  (red stain, A), 
and the abundance  of moderatdy strongly positive hepatocytes  in the periportal area (PT, portal tract, C) of the hepatic lobule.  (B) The sALT activity 
on day 2 after CTL administration to zinc treated (+)  and untreated (-) mice.  Experiments were performed in triplicate. 
1544  MHC Class I-restricted Immunopathogenesis Figure  4.  Sequential  histopathological  manifestations  of fulminant  hepatitis  after  CTL administration  in transgenic  mice. Histopathological  charac- 
teristics of transgenic  mouse  livers  observed  1-4 h (A, BrdU stain, original  magnification  x960), 4-12 h (B, BrdU stain, x960), and 72 h (C, hematox- 
ylin and eosin, ￿  200) after CTL administration  to transgenic  mice from lineages 107-5D and pFCS0-219D (E, hematoxylin  and eosin, x 200) the 
baseline intrahepatic  HBsAg  content  of  which  is demonstrated  by immunohistochemical  staining  for HBsAg  in D (107-5D, x 200) and F (pFC80-219D, 
x 200). (Asteruks)  Apoptotic  hepatoeytes;  (arrows) BrdU-positive  CTL; (arrowheads)  necroinflammatory  loci; (PT) portal tract; (CV) central vein. See 
text for description. 
3 C), similar to lineage 107-5 (Fig. 4 D) in which the large 
envelope polypeptide is constitutively  expressed under the con- 
trol of the albumin promoter (21). Interestingly, the CTL 
caused little or no hepatocellular injury in lineage 23-3  ~ 
1545  Ando et al. 
unless HBsAg was retained by the hepatocyte (Fig. 3 B), sug- 
gesting that the severity of CTL-induced liver disease is de- 
termined by the number of hepatocytes that retain HBsAg 
or by the concentration of HBsAg within each cell, or both. Histopatkological and Quantitative Morphometric Analysis of 
the Intrahepatic Inflammatory Cell Infiltrate in the Context of 
HBsAg Retention (Lineage 107-5) or Secretion (Lineage pFC80- 
219  ~)  by the Hepatocyte  Histopathological  (Fig.  4)  and 
quantitative  morphometric (Fig. 5) analysis of hematoxylin 
and eosin stained tissue sections was performed at frequent 
intervals throughout the course of the disease after the injec- 
tion  of  107  CTL  into  male  107-5D  recipients.  Lineage 
pFC80-219 ~  males were also examined histologically at a 
single time point (48 h) after CTL injection. In selected in- 
stances, the CTL were labded with BrdU before injection 
to permit them to be identified immunohistochemically in 
the tissue. 
The disease appeared to progress  through three distinct 
histopathological  stages in lineage  107-5D. The first stage 
(step 1) was heralded by the entry of BrdU-labded CTL into 
the hepatic parenchyma, within 1 h of intravenous CTL ad- 
ministration as shown in Figs. 4 A  (arrow) and 5 B. Over 
the next 4 h, CTL were observed to be attached to hepato- 
cytes that displayed the diagnostic cytological feature of apop- 
toffs (Ando, K. et al., manuscript submitted for publication). 
Specifically, the CTL-associated hepatocytes displayed mar- 
gination of nuclear chromatin and cytoplasmic condensation 
and fragmentation together with cellular shrinkage (Fig. 4 
A, asterisk), producing the well-known acidophil, or Coun- 
cilman, bodies that represent cytoplasmic fragments of apop- 
totic hepatocytes (Ando, K. et al., manuscript submitted for 
publication)  and are characteristic of viral hepatitis (31, 32). 
No other inflammatory cells were detectable in the vicinity 
of these lesions, or elsewhere within the liver at this time, 
indicating that the CTL were solely responsible for this effect. 
The sALT levels were normal or only very slightly elevated 
during this interval (Fig. 5 A), suggesting either that this 
enzyme was not released during this process, or that the 
number of apoptotic hepatocytes was insufficient to yield a 
significant increase in sALT activity. 
With the passage of time, the number of BrdU-positive 
CTL in the liver increased, reaching a plateau  of approxi- 
mately 22 CTL per mm  2 of liver tissue 4-12 h after injection 
(Fig. 5 B). During this interval, the number of BrdU-positive 
CTL (Fig. 4 B, arrow)-associated apoptotic hepatocytes (Fig. 
4 B, asterisks) also increased progressively, and many necro- 
inflammatory loci appeared, indicating onset of the second 
stage (step 2) in the disease process. In these loci, the CTL 
were surrounded by unlabeled (therefore host derived) inflam- 
matory cells, including cytologically distinguishable neutro- 
phils, lymphocytes,  and macrophages (Fig. 4 B, N, M, and 
L),  and necrotic hepatocytes were observed to be spatially 
distant  from the labeled CTL, suggesting that they might 
have been destroyed by non-CTL constituents within the 
necroinflammatory loci. Concomitant with the development 
of necroinflammatory loci 4-12 h after CTL injection, the 
number of cytologically apparent dead and degenerating he- 
patocytes in the liver increased substantially, and the sALT 
activity levels began to rise (Fig. 5 A). 
24-72 h after CTL injection, hepatocellular  necrosis be- 
came widespread throughout the lobule (panlobular), marking 
the third stage (step 3) of the disease. During this period, 
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Figure  5.  Kinetics and cell type of intrahepatic inflammatory infiltrate 
and liver cell injury. Quantitative morphometry of injured hepatocytes 
and intrahepatic inflammatory cells at multiple time points after the injec- 
tion of 107 clone 6C2 CTL into lineage 107-5 male transgenic mice. A 
minimum of 50 high power (x400) fields representing 2 mm  2 of liver 
tissue were examined. The number of dead and degenerating hepatocytes 
(A), BrdU-positive CTL (B), neutrophils and lymphocytes (C), and tissue 
macrophages  (/9) present in 3-/~M-thick  sections were expressed as the 
number of cells per mm  2 of liver tissue. The results reflect the mean of 
two observations (two mice) for each point. Serum ALT activity was mea- 
sured at the times indicated. 
the number of necrotic and degenerating hepatocytes and the 
sALT levels reached a peak (Fig. 5 A) from which they subse- 
quently declined in the surviving animals. Histopathologi- 
cally, at these time points,  the vast majority of hepatocytes 
were either frankly necrotic or displayed prelytic changes such 
as extreme cytoplasmic hydropic degeneration and ballooning, 
or apoptosis, in the context of an overwhelming inflammao 
tory reaction (Fig. 4 C). CoincidentaUy, the number of BrdU- 
negative, host-derived inflammatory cells also increased but, 
unlike the BrdU-positive  CTL which reached a plateau by 
12 h after CTL injection (Fig. 5 B), they continued to rise 
1546  MHC  Class I-restricted Immunopathogenesis for 72 h (Fig.  5,  C  and D), eventually outnumbering the 
CTL by at least 100-fold before they started to decline. Frozen 
sections fi'om selected  liven were examined immunohistochem- 
ically for lymphocyte and macrophage markers at this time 
point. Although precise quantitation was not possible, it was 
clear that cells of the monocyte/macrophage lineage domi- 
nated the inflammatory infiltrate,  and that a less abundant 
mixed population of L3T4 and Lyt-2-positive lymphocytes 
was also present, confirming the cytomorphological obser- 
vations described above. 
The foregoing disease occurred in the context of hepatocel- 
lular HBsAg retention in lineage 107-5D (Fig. 4 D). To in- 
vestigate the possibility that retention of HBsAg might con- 
tribute to the severity of liver disease in this model, as it does 
after the injection of bacterial LPS and IFN-3/into the same 
lineage of mice (24), we examined the histopathological char- 
acteristics of the CTL-induced liver disease in lineage pFC80- 
219D whose hepatocytes do not retain immunohistochemi- 
cally detectable HBsAg (Fig. 4 F). Interestingly, peak sALT 
levels achieved after CTL injection were <5% as high (288 
_+  47.9 U/liter, n  =  5) as the levels routinely achieved in 
lineage 107-5D. Histopathologically, thes~ animals displayed 
widely scattered apoptotic hepatocytes associated with BrdU- 
positive CTL (step 1) during the first few hours after CTL 
injection, and at the peak of disease, the liver contained mul- 
tiple, small necroinflammatory loci (Fig. 4 E, arrowheads) 
containing apoptotic hepatocytes (Fig.  4 E, asterisks)  that 
resembled a mild form of step 2 seen in lineage 107-5D (Fig. 
4 B). Importantly, the liver disease appeared to stop at this 
stage in lineage pFC80-219D. The data suggest, therefore, 
that HBsAg retention appears to play a very important, per- 
haps critical  role in disease progression from step 2 to step 
3 in this model, presumably by sensitizing the hepatocyte 
to additional events (see below) that lead to widespread pan- 
lobular necrosis  and hepatic failure. 
The Role oflFN-7.  Since clones D10 and 6C2 produce 
IFN-'), in vitro upon antigenic stimulation (Ando, K. et al., 
manuscript submitted for publication), and since we have pre- 
viously shown that the HBsAg-positive hepatocyte is exqui- 
sitely susceptible to destruction by an IFN-3,-dependent path- 
way in vivo (24),  we examined the ability of monoclonal 
anti-IFN-~/antibodies to mitigate the induction of liver dis- 
ease by the CTL. As shown in Fig. 6 A  for clone 6C2, the 
prior administration of anti-IFN-'), resulted in virtually com- 
plete inhibition (97% reduction) of CTL-induced liver cell 
injury (peak sALT activity 590 _+ 170 U/liter compared with 
17,883 _+ 1,011 U/liter) in the control group (p < 0.000005). 
Importantly, none of the six anti-IFN-q(-treated mice died 
after CTL injection, whereas the same number of CTL have 
been shown to be lethal for 7/15 age- and sex-matched animals 
that had not been pretreated with these antibodies (Fig. 2). 
Furthermore, when the anti-IFN-q( antibodies were admini- 
stered 24 h after the CTL, when sALT activity was >7,000 
U/liter, the course of the disease was promptly reversed and 
disease resolution was noticeably accelerated, such that sALT 
levels in the anti-IFN-3,-treated mice were significantly lower 
(p < 0.05) than the hamster IgG-treated control mice at all 
time points examined (data not shown). 
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Figure  6.  CTL-induced liver disease is mediated principally  by IFN-'y. 
Groups of three lineage 107-5D males were either injected intraperitoneally 
with 500/~g of hamster mAb to IFN-3' or hamster IgG (,4), or they were 
irradiated (900 rad) (B), or injected intraperitoneally  with carrageenan (C) 
1 d, 6 d, or daily for 5 d, respectively, before the injection of 10  ~ CTL. 
The severity of the resultant liver disease was measured as sALT activity. 
All points marked (*) are statistically significantly lower than the corre- 
sponding group of three age- and sex-matched  mice simultaneously in- 
jected with the same number of 6C2 CTL. 
The only histological abnormalities observed in lineage 107- 
5D mice that had been pretreated with antibodies to IFN-q/ 
was the presence of a few small necroinflammatory loci (Fig. 
7 B, arrowheads) containing apoptotic hepatocytes (Fig.  7 
B, asterisks),  similar to the early focal lesions normally ob- 
served in the absence of anti-IFN-3' treatment in this lineage 
(Fig. 4 B) and like the focal lesions characteristic of the most 
advanced stage of disease seen in lineage pFCS0-219D (Fig. 
4 E). Importantly, there was no evidence of the widespread 
hepatocellular necrosis seen in control mice after CTL injec- 
tion (Figs. 4 C and 7 A) even though the number of BrdU- 
labeled CTL present in the liver was the same as in control 
mice not injected with the anti-IFN-'y antibodies (data not 
shown). This correlated with a prominent reduction in sinu- 
soidal lining cell hyperplasia together with a substantial de- 
crease in the other components of the host-derived inflam- 
matory response (compare Fig. 7, A and B). These findings 
suggest that IFN-~/triggers the widespread hepatocellular 
necrosis  characteristic  of step 3 of the disease process,  but 
that it appears not to be involved in the induction of hepatocel- 
lular apoptosis or the development ofnecroinflammatory  loci. 
In contrast to these results,  mAbs to TNF-ot were only 
modestly protective against the CTL-induced liver disease. 
Pretreatment of CTL recipients with anti-TNF-ot reduced 
sALT levels by '~30% (p < 0.05, not shown) suggesting that 
TNF-o~ plays a much less important role than IFN-% con- 
sistent with the observation that CTL clone 6C2 does not 
secrete TNF-ot in suffident amounts to be detected in bioas- 
says in vitro (Ando, K. et al., manuscript submitted for pub- 
lication). To determine if either of these cytokines are directly cytotoxic for the HBsAg-positive hepatocyte, we monitored 
the release of ALT and LDH from primary cultures of lin- 
eage 107-5D  hepatocytes after 24 h of in vitro incubation 
with up to 25,000 U/liter of recombinant IFN-7 or 5,000 
U/liter of recombinant TNFc~. Neither cytokine was hepato- 
cytotoxic to primary transgenic or nontransgenic hepatocytes 
in vitro (data not shown), suggesting that the cytopathic effect 
of these cytokines, especially IFN-% in vivo is indirect, pre- 
sumably by recruitment and activation of antigen nonspecific 
host inflammatory cells. In separate studies, we also showed 
that the cytolytic activity of clones D10 and 6C2 are not medi- 
ated by IFN-qr in vitro (not shown). 
Effect of Irradiation.  To examine the role of host inflam- 
matory cells in the pathogenesis of CTL-induced liver dis- 
ease, mice were irradiated (900 rad) 6 d before CTL adminis- 
tration in order to destroy the radiation-sensitive hematopoietic 
elements that could be activated by cytokines released by the 
CTL. In these animals,  the number of splenocytes was re- 
duced to <1% of control levels at the time of CTL injection 
(data not shown). As illustrated in Fig. 6 B, the kinetics of 
liver disease was delayed ~,24 h by prior irradiation, sug- 
gesting that radiosensitive  inflammatory cells, such as ma- 
ture lymphocytes and PMN, may contribute to pathogenesis 
during the first 24 h after CTL injection. Interestingly, the 
necroinflammatory  loci (step 2) that characteristically appear 
during this time period, and are composed of lymphocytes, 
monocyte/macrophages,  and neutrophils, were greatly dimin- 
ished in size and number in the irradiated animals,  despite 
the development of apoptotic hepatocytes and broad zones 
of hypereosinophilic necrotic hepatocytes and the appearance 
of hyperplastic sinusoidal lining cells by 72 h after CTL ad- 
ministration (Fig.  7  C).  Importantly, although the  total 
number of splenocytes was greatly reduced by irradiation (see 
above), the number of splenic and hepatic macrophages, de- 
tectable histologically by carbon particle ingestion, was quan- 
titatively and qualitatively normal in irradiated animals (Fig. 
8 A). These results indicate that step 2 (necroinflammatory 
foci) of this disease process is mediated by CTL-activated radio- 
sensitive host-derived inflammatory ceils, and they suggest 
that radioresistant calls (e.g.,  monocyte/macrophages) are 
responsible for progression to  step  3  (widespread hepatic 
necrosis). 
Effects of Carrageenan.  Since tissue macrophages are known 
to be radioresistant and to be activated  strongly by IFN-3, 
(33-36), and since they are a major constituent of the intra- 
hepatic inflammatory cell infiltrate after transfer of CTL (Fig. 
5 D), we pretreated groups of CTL recipients with carrageenan 
to inactivate  tissue macrophages in order to assess the role 
they might play in this model. In these studies, carrageenan 
was injected intraperitoneally daily for 5 d before CTL injec- 
tion. Carrageenan administered in this manner is known to 
be toxic for tissue macrophages (26, 27, 36). As illustrated 
in Fig. 6 C, carrageenan treatment reduced the severity of 
liver disease by >85% at all time points (p <0.0005),  sug- 
gesting that carrageenan-sensitive  cells (presumably macro- 
phages) play an important role in this disease model. As shown 
in Fig. 8 B, the number of carbon particle-positive phago- 
cytic cells in the liver and spleen were either greatly reduced 
or abolished, respectively, after treatment with carrageenan. 
Whereas this was associated with a profound reduction in 
the widespread hepatic necrosis (step 3) normally seen in the 
context of HBsAg retention in this model, carrageenan treat- 
merit had no effect on the development of hepatocellular apop- 
toffs (Fig. 7 D, asterisks) or necroinflammatory loci (Fig. 7 
D, arrowheads), indicating that carrageenan did not inhibit 
these direct or indirect effects of the CTL. Furthermore, it 
is important to note that carrageenan alone had no effect on 
sALT levels in control animals (data  not shown). 
Collectively,  the foregoing observations suggest that step 
1 in this disease process is caused by a direct effect of the 
CTL on the hepatocyte, that step 2 is mediated by radiosen- 
sitive, carrageenan-resistant  inflammatory cells that are acti- 
vated by one or more antigen nonspecific CTL products that 
have not yet been identified, and that step 3 reflects the selec- 
tive destruction of hepatocytes that retain HBsAg by car- 
rageenan-sensitive, radiation-resistant phagocytic cells that have 
been activated by IFN-3, secreted by antigen-reactive CTL. 
The data also suggest that disease evolution to step 3 does 
not require passage through stage 2. 
Discussion 
The current study describes the immunopathological  char- 
acterization  of a  fatal  necroinflammatory liver  disease  in 
HBsAg-positive transgenic mice that is initiated by HBsAg- 
specific, MHC  class I  (Ld)-restricted,  CD8-positive CTL 
clones that secrete IFN-3, after antigen recognition. Several 
features of this experimental system created the opportunity 
to dissect the molecular and cellular mechanisms responsible 
for dass I-restricted immunopathology in vivo, in a disease 
model that dosdy resembles HBV-induced fulminant hepatitis. 
First, the class I-restricted CTL clones employed in these 
Figure  7.  Modulation of CTI~induced liver disease by irradiation, anti-IFN-% and carrageenan.  Histopathological characteristics  of liver disease 
72 h after CTL administration to otherwise untreated transgenic mice (A), mice pretreated with antibodies to IFN-7 (B), irradiated with 900 tad 
(C), or injected with carragcenan  (D). (A) Note the mix~ inflammatory cell infiltrate throughout the hepatic lobule extending from the portal tract 
(PT) to the central vein (CV), and the accompanying broad zones of hepatocellular necrosis,  microvesicular  steatosis, and ballooning degeneration. 
Note also the presence of many hyperplastic sinusoidal  lining cells widely distributed throughout the section.  (B) Note the absence of widespread 
necrosis compared with A and C, and the marked reduction in inflammatory cells despite the prtmnce of apoptotic hepatocytes (*). Rare, small necroinflamma- 
tory loci are observed (arrowheads), representing the most severe manifestation of the disease observed in these animals. Note also that the sinusoidal 
lining cells appear to be less hyperplastic than in A, C, and D. (C) Note the marked reduction of inflammatory cells but the presence of many hyperplastic 
sinusoidal lining cells and a broad zone of necrotic hepatocytes  displaying condensed eosinophilic cytoplasm that extends diagonally across the field 
toward the central vein. Apoptotic hepatocytes  are plentiful within the field (*). (D) Note the absence of widespread necrosis compared with A  and 
C despite a fairly abundant, mixed inflammatory cell infiltrate and hyperplastic sinusoidal lining ceils, numerous apoptotic hepatocytes (*) and multiple 
necroinflammatory loci (arrowheads). This is the most severe stage in the CTL,  induced lesion observed in carragcenan-treated mice. All pands stained 
with hematoxylin and eosin;  original magnification  x 200). 
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phagocytic cells in disease pathogenesis. 
Groups of three lineage 107-5D males 
were either irradiated (900 tad) or in- 
jected  intraperitoneally  with  carra- 
gcenan  6  d before,  or daily  for 5  d, 
respectively, before the injection of 107 
CTL. Mice were injected intravenously 
with India ink on day 2 after CTL (to 
permit  assessment of phagocytic  cells 
in  situ)  and  they  were  killed  for 
histopathological analysis on day 3. (.4) 
Note the presence of numerous  black 
pigment (carbon partide)-laden mac- 
rophages  in  the  hepatic  sinusoids 
(arrows)  and in the collapsed marginal 
zone of the splenic white pulp  (inset) 
indicating the radioresistant properties 
of this cell type, in contrast to the rela- 
tive paucity of nonphagocytic  inflam- 
matory cells in both  tissues. Despite 
depletion  of radiosensitive cells, many 
apoptotic (*) and necrotic hepatocytes 
are present in the liver. (B) In contrast, 
depletion  of phagocytic cells in carra- 
geenan-treated animals, evidenced by a 
marked  reduction  in  the  number  of 
carbon  particle-laden  macrophages in 
the liver (arrow) and the splenic white 
pulp  (inset),  liver  disease  severity  is 
markedly decreased, even though both 
tissues display abundant  numbers  of 
carbon particle negative, i.e., nonphago- 
cytic, inflammatory cells in both tissues. 
studies are specific for an epitope (HBsAg25-39) which is con- 
served in all known HBV isolates.  Furthermore,  all of the 
CTL lines and clones that we have established  thus far in 
B10.D2 mice have displayed the same antigenic fine specifidty 
suggesting that this epitope is immunodominant in the con- 
text  of  the  H-2  a haplotype.  Additionally,  it  overlaps  an 
HLA-A2-restricted  CTL epitope that is recognized by pa- 
tients with acute viral hepatitis  (Chisari,  F. V., unpublished 
observations)  and it also overlaps an HLA-DPw4-restricted 
helper T  cell epitope that is recognized by HBsAg vaccine 
recipients  (37, 38).  Thus, it would appear that  this highly 
conserved  viral  sequence  is  also  highly immunogenic  for 
human T cells, and therefore it may be relevant in the patho- 
genesis of viral hepatitis  in humans. Second, HBsAg is ex- 
pressed in 100% of the hepatocytes  in two of the lineages 
(107-5 and pFC80-219) used in this study (22), so that every 
hepatocyte is a potential target for cytolytic attack when the 
CTL are transferred in vivo. Third, the HBsAg-positive he- 
patocyte is known to be exquisitely sensitive to the hepatocyto- 
toxic effects of IFN-3  ~ (24) which is produced  by the CTL 
clone used in this study,  and by all of the HBsAg-specific 
CTL clones we have derived  thus far. Fourth,  the unique 
microanatomy of the hepatic sinusoid, which contains a dis- 
continuous endothelium and lacks a basement membrane (39, 
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access to the target hepatocytes, which they have the poten- 
tial to kill,  and to the resident intrahepatic macrophages 
(Kupffer cells), which they have the potential to activate. Fi- 
nally, CTL entry and localization within the liver, their ability 
to bind and kill the HBsAg-positive hepatocyte, and their 
capacity to activate an intrahepatic inflammatory response can 
all  be  experimentally identified and  quantitated,  thereby 
making each of these aspects of CTL function individually 
discernible in vivo in this model. 
Taking advantage of these features, we demonstrated that 
the CTL-induced necroinflammatory liver disease displays 
stepwise progression from single cell necrosis to massive de- 
struction of most hepatocytes, and it displays most of the 
immunohistochemical and histopathological characteristics 
of HBV-induced acute hepatitis in humans. The stepwise na- 
ture of the disease process was evident upon quantitative mor- 
phometric histopathological analysis of the liver at increasing 
time points after the injection of BrdU-labeled CTL. 
Step 1 begins, within 1 h of CTL administration, with 
antigen recognition by the CTL and delivery of a signal that 
results in the death of the hepatocyte by a process that dis- 
plays all of the cytological criteria of apoptosis. The fact that 
this process is not inhibited by the prior administration of 
antibodies to IFN-3, indicates that it is not mediated by this 
cytokine. This event appears to be pathogenetically limited 
to very few cells, however, possibly because free-ranging CTL 
movement is severely limited by the architectural constraints 
of solid tissue. The direct CTL-target cell interaction results 
in widely scattered,  acidophilic, Councilman bodies (apop- 
totic hepatocytes) that are characteristic  of acute viral hepa- 
titis in humans (31, 32). As we have recently reported in de- 
tail (Ando, K. et al., manuscript submitted for publication), 
this model provides the first definitive demonstration that 
class I-restricted CTL can directly destroy their target cells 
in vivo. 
Step 2 begins 4-12 h later, when the CTL recruit many 
BrdU-negative (i.e., host-derived) inflammatory cells into their 
immediate vicinity, resulting in the formation of necroinfhm- 
matory loci and the extension of hepatocellular apoptosis and 
lysis to the periphery of necroinflammatory loci well beyond 
the CTL.  The histopathological features  of step 2  were 
abrogated by lethal irradiation,  which also caused a 24-h delay 
in the disease process, indicating that radiation-sensitive lym- 
phocytes and nentrophils probably contribute importantly 
to this aspect of the disease. On the contrary, it would ap- 
pear that the circulating monocytes and intrahepatic sinu- 
soidal macrophages (Kupffer cells) do not play a major role 
in step 2, since the number of phagocytically active macro- 
phages in the liver was not affected by irradiation, and since 
necroinflammatory loci were observed in mice whose intra- 
hepatic macrophages had been functionally inactivated by the 
prior injection of carrageenan.  Although we presume that 
step 2 is mediated by secretion of one or more cytokines by 
the antigen-activated CTL, this component of the disease was 
not completely blocked by anti-IFN-3~ antibodies, suggesting 
either that IFN-~ is not necessary for development of this 
stage of the disease, or that the antibodies failed to ef~ciently 
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reach the interior of these necrotic loci. The latter is unlikely 
in view of the profound effect of anti-IFN-3~ on step 3 in 
the disease  process. Because the histopathology of typical acute 
viral hepatitis in humans (31, 32) is quite similar to the mouse 
liver at this stage (apoptotic hepatocytes, focal necroinflamma- 
tory lymphomononuclear  cell infiltrates and Kupffcr cell hyper- 
plasia), it is quite possible that the same events that are respon- 
sible for steps 1 and 2 in the current disease model may be 
pathogenetically responsible for the liver disease typical of 
acute,  nonfatal viral hepatitis B in humans. 
Step 3 is detectable 24--72 h after CTL administration, when 
the livers display massive hepatoceUular necrosis and an inflam- 
matory cell infiltrate that consists principally of host-derived 
lymphomononuclear  cells and pronounced sinusoidal lining 
cell (Kupffer cell?) hyperplasia,  resembling the histopatho- 
logical changes observed in patients dying from liver failure 
due to HBV-induced fulminant hepatitis (31). The inflam- 
matory cells,  especially  the  monocyte/macrophages, out- 
number the injected CTL by at least 100-fold at this point 
in the disease process, suggesting that they might serve to 
amplify the cytopathic effects of the CTL to the extent of 
massive hepatoceUular necrosis and the death of the mouse. 
Since the pathogenetic effect of the CTL was reduced more 
than 97% by the prior administration of neutralizing mAbs 
to IFN-% which also reduced the CTL-induced mortality 
rate to zero, it would appear that this cytokine is principally 
responsible for the extreme severity of the liver disease in this 
model. 
IFN-'y is known to activate macrophages (33-35) and to 
mediate the recruitment of lymphocytes into typical class II-re- 
stricted DTH reactions (41). This cytokine is also known to 
be secreted by many CD8 § murine clones in response to an- 
tigenic stimulation (42). Accordingly, it has been shown that 
CTL-induced clearance of influenza virus in vivo correlates 
with the ability of the virus-specific CTL clones to secrete 
IFN-3, and induce a DTH reaction upon exposure to antigen 
(43).  Interestingly, tumor regression mediated by cultured 
tumor-infiltrating CD8 § lymphocytes correlates better with 
their ability to secrete IFN-3, than with their cytotoxic poten- 
tial in vitro (44), and several groups have shown that tumor 
regression can be induced by a DTH reaction that is medi- 
ated by IFN-y activated macrophages (27, 33, 34, 45, 46). 
Furthermore, CD8 + T  cell protection in rodent models of 
Plasmodium berghei (47) and Toxoplasma gondii infection (48) 
are dependent on IFN-%  although the control of murine 
Listeria monocytogenes infection by CD8 + T cells appears to 
be independent of IFN-'y (49). Finally, Doherty et al. (50) 
have suggested that LCMV-induced murine choriomeningitis 
may be mediated by a massive DTH reaction that is trig- 
gered by relatively few virus-immune CD8-positive T cells 
but is composed principally of antigen-nonspecitic monocytes 
and macrophages. 
In view of the foregoing, and since the severity of liver 
disease in the current model was also profoundly reduced in 
mice whose macrophage function had been blocked by mul- 
tiple injections of carrageenan,  we conclude that IFN-'y acti- 
vated intrahepatic macrophages are probably responsible for 
the massive, fatal hepatocellular necrosis characteristic of step 3 in this model.  Based on previous reports  that  apoptotic 
cells can prime macrophages to activation by IFN-'y in vitro 
(43), it is possible (although not proven) that CTL-induced 
hepatocelluhr apoptosis might cooperate with IFN-'y to create 
the massive lesion we observed in these animals. It is impor- 
tant to emphasize that the extreme severity of this phase of 
the disease process (step 3) depends on the fact that HBsAg 
retention sensitizes the hepatocyte to the cytopathic effects 
of IFN-3' (25) since the disease did not progress beyond step 
2 in lineage pFC80-219D whose hepatocytes secrete HBsAg 
rather than retain it. We conclude, therefore, that the CTL 
serve as highly ef~dent IFN-3, delivery vehicles,  resulting in 
widespread activation of intrahepatic  macrophages that,  in 
the context of widespread HBsAg retention,  eventually de- 
stroy most or all of the HBsAg-positive hepatocytes and kill 
the mice. Additional studies will be necessary to identify the 
specific macrophage function or product that is responsible 
for this devastating effect. 
Although  our  data  indicate  that  class  I-restricted  im- 
munopathology is a stepwise process in this model system, 
it is likely that the three steps are sequential yet independent 
responses to differing signals delivered by antigen-activated 
CTL.  In view of the close physical approximation  of CTL 
and hepatocyte and the associated cytological features of apop- 
toffs, it would appear that  step 1 represents a direct effect 
of the CTL in vivo, similar to the ability of CTL to induce 
apoptosis by direct interaction with target ceils in vitro. Apop- 
tosis, however, is usually not a proinflammatory event. Ac- 
cordingly, we suggest that the focal (step 2) and generalized 
(step 3) necroinflammatory reactions that occur later in this 
model are due to independent indirect functions of the CTL 
that are mediated by IFN-'y and other currently unidentified 
cytokines. 
Based on the similarities between this model and the im- 
mfinopathological features of human viral hepatitis,  with most 
cases of acute and chronic hepatitis displaying the histolog- 
ical  features  of steps  1  and  2,  while  fulminant  hepatitis 
resembles progression to step 3, we suggest that comparable 
events contribute to the pathogenesis of liver disease during 
HBV infection in humans. We also suggest that the general 
principles iUustrated in this study may be applicable to other 
models of class  I-restricted immunopathology  as well. 
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